YB1 Pharmaceutucal Limited is a leading biopharmaceutical company specializing in innovative drug development in the field of targeted cancer therapy. With their world-leading synthetic biology-based oncolytic bacterial delivery platform, they offer revolutionary cancer immunotherapy solutions. YB1, a genetically programmed strain of Salmonella typhimurium, is their groundbreaking oncolytic bacterial therapy.

It has exhibited exceptional safety, efficacy, and versatility. YB